Redeye: AVTECH - Staying on Course
Redeye updates its sales estimate for Q3 and Q4 by ~-10% while keeping its fair value range. Considering the many ongoing trials, we see potential catalysts in Q3 or Q4.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/